title: Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
abstract: In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death without relapse) is 1.27, 95% CI = 0.87 - 1.85.] There is a suggestion that therapy for longer than 5 years may increase the risk of endometrial carcinoma (P = 0.064).
authors.affiliation: Scottish Cancer Trials Office, Medical School, University of Edinburgh, UK.
authors.forename: H J
authors.initials: HJ
authors.lastname: Stewart
authors.forename: A P
authors.initials: AP
authors.lastname: Forrest
authors.forename: D
authors.initials: D
authors.lastname: Everington
authors.forename: C C
authors.initials: CC
authors.lastname: McDonald
authors.forename: J A
authors.initials: JA
authors.lastname: Dewar
authors.forename: R A
authors.initials: RA
authors.lastname: Hawkins
authors.forename: R J
authors.initials: RJ
authors.lastname: Prescott
authors.forename: W D
authors.initials: WD
authors.lastname: George
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen